Chemclin Diagnostics(SH:688468) Sou Hu Cai Jing·2025-05-29 12:35Group 1 - The core viewpoint of the articles highlights the performance and market position of Kemei Diagnostics, noting its stock price increase and current valuation metrics [1][2] - Kemei Diagnostics closed at 7.28 yuan, with a rise of 2.68%, resulting in a rolling PE ratio of 28.29 times and a total market capitalization of 2.92 billion yuan [1] - The average PE ratio for the medical device industry is 49.64 times, with a median of 36.36 times, placing Kemei Diagnostics at the 63rd position in the industry ranking [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business involves the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments, with key products including the LiCA and CC series [1] - In the reporting period, Kemei Diagnostics obtained 64 new domestic and international patents, showcasing its ongoing innovation capabilities and technological reserves [1] - The latest quarterly report for Q1 2025 indicates that the company achieved operating revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]